Human stem cell models of lung adenocarcinoma
Human stem and progenitor-based models of lung adenocarcinoma
This project builds improved lab-grown human lung cancer models from patient cells to better reflect how lung adenocarcinoma develops and responds to treatments.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11238552 on NIH RePORTER |
What this research studies
If you donate tissue, researchers will use human lung stem and progenitor cells to grow lab models that more closely match human lung adenocarcinoma than standard mouse tumors. They will introduce specific mutations and control tumor stage so the models mimic how cancers start and change in people. The team will compare these new models to existing patient-derived organoids and mouse models to see which best reflects the human disease. These human-relevant models could be used to test how tumors respond to different therapies, including immune-based treatments.
Who could benefit from this research
Good fit: Adults with lung adenocarcinoma who can provide tumor tissue or surgical biopsy samples, typically through the treating hospital, would be ideal candidates to contribute samples.
Not a fit: People without lung cancer, with other lung cancer subtypes not related to adenocarcinoma, or those unable/unwilling to provide tissue are unlikely to benefit directly from participation.
Why it matters
Potential benefit: If successful, these models could help scientists develop and test treatments that better match the biology of human lung adenocarcinoma.
How similar studies have performed: Patient-derived organoids and xenografts have shown promise in some cancers, but stem/progenitor-based human models for lung adenocarcinoma are relatively new and not yet widely validated.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Kadur Lakshminarasim, Preetish — University of Illinois at Chicago
- Study coordinator: Kadur Lakshminarasim, Preetish
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.